Company / Operating Income
Oric Pharmaceuticals, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$143.0M
FY2025
5-year range
-$143.0M / -$78.9M
FY2021-FY2025
Trend
-0.1%
vs FY2024
Sector context
#112 of 204
Health Care
What the data says
At -$143M, Oric Pharmaceuticals, Inc.'s operating income ranks #112 of 204 in the Health Care sector. Operating Income has declined for 7 consecutive years, from -$22M in FY2018 to -$143M in FY2025.
Based on SEC 10-K filings.
-$143M in FY2025.
Declined from -$111M to -$143M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#112 of 204 in Health CareTop 55% of 204This company -$143.0M Sector average $107.7M
▼
-232.8% below sector average
Key checks
Key Insights
- Oric Pharmaceuticals, Inc.'s operating income has declined for 7 consecutive years.
- In FY2025, operating income decreased 0.1% year-over-year.
- Ranks #112 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$143.0M | -0.1% |
| FY2024 | -$142.9M | -29.0% |
| FY2023 | -$110.8M | -20.7% |
| FY2022 | -$91.8M | -16.4% |
| FY2021 | -$78.9M | -6.3% |
| FY2020 | -$74.2M | -159.7% |
| FY2019 | -$28.6M | -27.7% |
| FY2018 | -$22.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026